Navigation Links
Velos, Inc. Introduces Mobile App for Oncology Adverse Events and Graft-Versus-Host Disease at 2012 ASCO Annual Meeting
Date:5/31/2012

FREMONT, Calif., May 31, 2012 /PRNewswire/ -- Velos, Inc. today announced the release of Velos Aversi, an iPad app for clinicians in oncology and bone marrow transplantation. The app is now available for download on the Apple App Store.

On Saturday, June 2, 2012 7:00 am CDT at the 2012 ASCO Annual Meeting in Chicago, Illinois, Dr. Roy Jones, MD, PhD, from the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center in Houston, Texas, will give a talk on the approach to improving patient safety, care, and adverse event management with Velos Aversi. Demonstrations of Velos Aversi will also be available at the Velos ASCO booth (#19118) throughout the conference.

Velos Aversi is designed to record, track, and export patient adverse events (AE) and Graft-Versus-Host Disease (GVHD) at point-of-care in hospital and ambulatory care settings. With a few touches on the iPad, clinicians, physicians, and research nurses can review and manage their patients' AE and GVHD histories anytime, anywhere—freeing them from large and cumbersome paper files. The app allows for more accurate attribution and reduces transcription errors that can occur when AE data entry is delayed. Direct and immediate input by clinicians saves time and ensures the quality of the record, particularly when grading events. Reliance on static, unconnected documents and systems to record AEs and GVHD in clinical trials and after transplants has been costly in terms of missed events, failure to record, multiple duplicate records, variations on scale or grade, and the need to review multiple streams of data (labs, notes, etc.) prior to recording an event.

Velos Aversi solves these problems through pre-loaded AE or GVHD scores from previous patient encounters and combined data collection for AEs and GVHD. Velos Aversi is also available in tandem with other Velos offerings, including Velos eResearch. Velos now offers a suite of products that tracks labs, adverse events, and appropriate rules and workflows.

 "It's an exciting time to be in the healthcare information technology field," said John McIlwain, CEO and President of Velos. "With Velos Aversi, we are bringing adverse event and safety information to the palm of the clinician's hand. Clinicians needed a simple, no-nonsense way to manage adverse events. That's Velos Aversi."

There has been growing interest and feedback from clinicians over the past few months since Velos Aversi was first unveiled to the bone marrow transplant community at the 2012 Blood and Marrow Transplantation (BMT) Tandem Meetings in February 2012. Velos continues to encourage the user community to send additional feedback to aversiapp@velos.com.

About Velos – Velos is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S.  Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. System users are freed of redundant data entry and related time delays associated with most clinical research today. Velos integrates the clinical, administrative and financial information needs of research management, with an emphasis on flexibility and workflow. Founded in 1996, Velos, Inc. is privately held with headquarters in Fremont, California.  For more information, visit http://www.velos.com/.

*This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.


'/>"/>
SOURCE Velos, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
2. Velos, Inc. Partners With Comaiba
3. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
4. Dr. Dello Russo Introduces the New EYE-Q Lasik
5. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
6. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
7. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
8. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
9. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
10. Siemens Introduces New Standard of Care for Breast Ultrasound
11. Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimers Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- LG Innotek hat heute die weltweit erste 70 mw ... 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C LED ... 280 nm und eignet sich damit für Sterilisationsaufgaben. Es verhindert ... Das Produkt von LG Innotek erzeugt UV-Strahlung im Bereich ... ...
(Date:2/23/2017)... and Markets has announced the addition of the "Menopause Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Menopause ... market? What are the unit prices and annual treatment ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... An in-depth computational analysis of genetic variants implicated in both ... genes that may explain why susceptibility to one of the disorders could place individuals ... today in the journal npj Schizophrenia. , “There is a wealth of genomic ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT ... top priority because it’s not if you will be attacked, but when.” However, he ... comes to digital health care. , Improvements in auditing and monitoring have taken security ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal ... Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, ... his attempts to overcome them. , Schanssema, initially unsure of the career path he ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... ... The Radiology Business Management Association will select the 2017 Quest ... Better Radiology Marketing Programs conference, held this year from March 5 to 7 ... given out in five categories. They are:, ,     Patient Marketing, a ...
Breaking Medicine News(10 mins):